Welcome to our dedicated page for ImmunityBio SEC filings (Ticker: IBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ImmunityBio, Inc. filings document the formal reporting record for a commercial-stage immunotherapy company with Nasdaq-listed common stock. Form 8-K reports furnish operating results, ANKTIVA product revenue updates, regulatory authorizations for ANKTIVA with BCG in NMIBC, FDA promotional-compliance correspondence, and material agreements including revenue interest purchase agreement amendments and convertible promissory note amendments.
Proxy materials cover board elections, executive compensation, equity awards, pay-versus-performance data, and shareholder voting matters. The filings also describe capital structure and financing obligations, related-party arrangements, and risk factors tied to clinical development, regulatory review, manufacturing and supply, commercialization, reimbursement, competition, and market acceptance.
ImmunityBio, Inc. director Barry J. Simon reported an open-market sale of common stock. On June 24, 2026, he sold 25,000 shares at a weighted average price of $7.8763 per share, in a trade executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 18, 2025. After this transaction, he continues to hold 2,802,788 shares of ImmunityBio common stock directly.
ImmunityBio director Michael D. Blaszyk received a grant of stock options covering 65,600 shares of common stock. The options have an exercise price of $7.25 per share and expire on June 9, 2036.
According to the award terms, subject to his continuing to be a Service Provider under ImmunityBio’s 2025 Equity Incentive Plan, 100% of the shares subject to the option will vest on the earlier of June 9, 2027 or the date immediately before the next annual stockholder meeting.
ImmunityBio director Wendel Bruce received a new stock option grant as part of his compensation. He was awarded options covering 65,600 shares of ImmunityBio common stock at an exercise price of $7.25 per share, with no cash paid at grant.
These options vest 100% on the earlier of June 9, 2027 or the date immediately before the next annual stockholder meeting, as long as he continues as a service provider under the company’s 2025 Equity Incentive Plan. The options expire on June 9, 2036, giving a long-term incentive tied to the company’s share price.
ImmunityBio director Linda Maxwell received a grant of stock options covering 65,600 shares of Common Stock. The options have an exercise price of $7.25 per share and expire on June 9, 2036.
All 65,600 shares subject to the award will vest in a single tranche, provided she continues as a “Service Provider” under the company’s 2025 Equity Incentive Plan, on the earlier of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders. Following this award, she holds 65,600 options directly.
ImmunityBio director Wesley Clark received a new stock option grant. The award covers 65,600 shares of Common Stock at an exercise price of $7.25 per share and expires on June 9, 2036. All 65,600 options vest 100% on the earlier of June 9, 2027 or the date immediately before the next annual stockholder meeting, if he continues as a service provider.
ImmunityBio director Cheryl Cohen received a new stock option grant. She was awarded options to buy 65,600 shares of ImmunityBio common stock at an exercise price of $7.25 per share, expiring on June 9, 2036. This is a compensation-related award, not an open-market purchase.
The option vests in full only if she continues as a service provider. All 65,600 shares underlying the award will vest on the earlier of June 9, 2027 or the date immediately before the next annual meeting of stockholders. Following this grant, she holds 65,600 stock options directly.
ImmunityBio, Inc. director Christobel Selecky received a grant of stock options covering 65,600 shares of common stock. The options have an exercise price of $7.25 per share and expire on June 9, 2036.
Subject to Selecky continuing as a “Service Provider” under the company’s 2025 Equity Incentive Plan, 100% of the options will vest on the earlier of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders. Following this grant, Selecky holds 65,600 stock options directly.
ImmunityBio, Inc. reported results of its 2026 Annual Meeting of Stockholders held on June 9, 2026. Of 1,047,345,861 common shares outstanding as of April 13, 2026, 885,167,059 shares were represented, about 85% of eligible shares, establishing a quorum.
Stockholders re-elected nine directors, including Patrick Soon-Shiong, M.D., Cheryl L. Cohen, and seven other nominees, each to a one-year term ending at the 2027 annual meeting. Stockholders also ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 882,420,139 votes in favor.
ImmunityBio director Barry J. Simon reported an open-market sale of 23,033 shares of Common Stock at a weighted average price of $7.1769 per share. The sale was executed on June 4, 2026 under a pre-arranged Rule 10b5-1 trading plan. After the transaction, he directly holds 2,827,788 shares.